139 related articles for article (PubMed ID: 21777350)
21. Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML.
Volk A; Li J; Xin J; You D; Zhang J; Liu X; Xiao Y; Breslin P; Li Z; Wei W; Schmidt R; Li X; Zhang Z; Kuo PC; Nand S; Zhang J; Chen J; Zhang J
J Exp Med; 2014 Jun; 211(6):1093-108. PubMed ID: 24842373
[TBL] [Abstract][Full Text] [Related]
22. Stromal cells attenuate the cytotoxicity of imatinib on Philadelphia chromosome-positive leukemia cells by up-regulating the VE-cadherin/β-catenin signal.
Chen C; Zhang HX; Wang M; Song XG; Cao J; Wang L; Qiao JL; Lu XY; Han ZX; Zhu P; Pan B; Wu QY; Zhao K; Yan ZL; Li ZY; Zeng LY; Xu KL
Leuk Res; 2014 Dec; 38(12):1460-8. PubMed ID: 25443888
[TBL] [Abstract][Full Text] [Related]
23. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
Tatetsu H; Okuno Y; Nakamura M; Matsuno F; Sonoki T; Taniguchi I; Uneda S; Umezawa K; Mitsuya H; Hata H
Mol Cancer Ther; 2005 Jul; 4(7):1114-20. PubMed ID: 16020669
[TBL] [Abstract][Full Text] [Related]
24. A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice.
Funakoshi T; Yamashita K; Ichikawa N; Fukai M; Suzuki T; Goto R; Oura T; Kobayashi N; Katsurada T; Ichihara S; Ozaki M; Umezawa K; Todo S
J Crohns Colitis; 2012 Mar; 6(2):215-25. PubMed ID: 22325176
[TBL] [Abstract][Full Text] [Related]
25. IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells.
Watanabe M; Dewan MZ; Taira M; Shoda M; Honda M; Sata T; Higashihara M; Kadin ME; Watanabe T; Yamamoto N; Umezawa K; Horie R
Lab Invest; 2007 Apr; 87(4):372-82. PubMed ID: 17310217
[TBL] [Abstract][Full Text] [Related]
26. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
Wakamatsu K; Nanki T; Miyasaka N; Umezawa K; Kubota T
Arthritis Res Ther; 2005; 7(6):R1348-59. PubMed ID: 16277688
[TBL] [Abstract][Full Text] [Related]
27. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
[TBL] [Abstract][Full Text] [Related]
28. Molecular design and biological activities of NF-kappaB inhibitors.
Umezawa K; Chaicharoenpong C
Mol Cells; 2002 Oct; 14(2):163-7. PubMed ID: 12442886
[TBL] [Abstract][Full Text] [Related]
29. Synergistic effect of 5-azacytidine and NF-κB inhibitor DHMEQ on apoptosis induction in myeloid leukemia cells.
Togano T; Nakashima M; Watanabe M; Umezawa K; Watanabe T; Higashihara M; Horie R
Oncol Res; 2012; 20(12):571-7. PubMed ID: 24139415
[TBL] [Abstract][Full Text] [Related]
30. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
Kuroda J; Kimura S; Segawa H; Kobayashi Y; Yoshikawa T; Urasaki Y; Ueda T; Enjo F; Tokuda H; Ottmann OG; Maekawa T
Blood; 2003 Sep; 102(6):2229-35. PubMed ID: 12763930
[TBL] [Abstract][Full Text] [Related]
31. Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.
Ohsugi T; Kumasaka T; Okada S; Ishida T; Yamaguchi K; Horie R; Watanabe T; Umezawa K
Cancer Lett; 2007 Nov; 257(2):206-15. PubMed ID: 17764832
[TBL] [Abstract][Full Text] [Related]
32. Aberrant expression of NF-κB in liver fluke associated cholangiocarcinoma: implications for targeted therapy.
Seubwai W; Wongkham C; Puapairoj A; Khuntikeo N; Pugkhem A; Hahnvajanawong C; Chaiyagool J; Umezawa K; Okada S; Wongkham S
PLoS One; 2014; 9(8):e106056. PubMed ID: 25170898
[TBL] [Abstract][Full Text] [Related]
33. Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia.
Cerny-Reiterer S; Meyer RA; Herrmann H; Peter B; Gleixner KV; Stefanzl G; Hadzijusufovic E; Pickl WF; Sperr WR; Melo JV; Maeda H; Jäger U; Valent P
Oncotarget; 2014 Mar; 5(5):1198-211. PubMed ID: 24681707
[TBL] [Abstract][Full Text] [Related]
34. Blocking ATM-dependent NF-κB pathway overcomes niche protection and improves chemotherapy response in acute lymphoblastic leukemia.
Chen YL; Tang C; Zhang MY; Huang WL; Xu Y; Sun HY; Yang F; Song LL; Wang H; Mu LL; Li MH; Zheng WW; Miao Y; Ding LX; Li BS; Shen SH; Liu SL; Li H; Zhu ZQ; Chen HW; Tang ZH; Chen J; Hong DL; Chen HZ; Duan CW; Zhou BS
Leukemia; 2019 Oct; 33(10):2365-2378. PubMed ID: 30940905
[TBL] [Abstract][Full Text] [Related]
35. Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation.
Dabaghmanesh N; Matsubara A; Miyake A; Nakano K; Ishida T; Katano H; Horie R; Umezawa K; Watanabe T
Cancer Sci; 2009 Apr; 100(4):737-46. PubMed ID: 19469019
[TBL] [Abstract][Full Text] [Related]
36. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ.
Miyake A; Dewan MZ; Ishida T; Watanabe M; Honda M; Sata T; Yamamoto N; Umezawa K; Watanabe T; Horie R
Microbes Infect; 2008 Jun; 10(7):748-56. PubMed ID: 18538617
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and structure-activity relationship of dehydroxymethylepoxyquinomicin analogues as inhibitors of NF-kappaB functions.
Chaicharoenpong C; Kato K; Umezawa K
Bioorg Med Chem; 2002 Dec; 10(12):3933-9. PubMed ID: 12413845
[TBL] [Abstract][Full Text] [Related]
38. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes.
Shukla S; Gupta S
Clin Cancer Res; 2004 May; 10(9):3169-78. PubMed ID: 15131058
[TBL] [Abstract][Full Text] [Related]
39. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
40. The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.
Celegato M; Borghese C; Umezawa K; Casagrande N; Colombatti A; Carbone A; Aldinucci D
Cancer Lett; 2014 Jul; 349(1):26-34. PubMed ID: 24704296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
